Topical prostaglandins for glaucoma therapy

Journal of Glaucoma

Volumn 6, Issue 3, 1997, Pages 180-187

  Wyse, Tamara B ^a   Talluto, Donna M ^a   Krupin, Theodore ^a,b   Rosenberg, Lisa F ^a   Ruderman, Jon M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; PILOCARPINE; PROSTAGLANDIN; TIMOLOL; UNOPROSTONE ISOPROPYL ESTER;

BLOOD EYE BARRIER; CONJUNCTIVA DISEASE; DRUG EFFICACY; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BLOOD-AQUEOUS BARRIER; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS; SAFETY;

EID: 0030786909     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (77)

1. Goldyne ME. Prostaglandins and other eicosanoids. In: Katzung BG, ed. Basic and Clinical Pharmacology. Norwalk, CT: Appleton & Lange, 1987:211-21.
2. Kulkarni PS, Srinivasan BD. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:39-52.
3. Polansky JR, Kurtz RM, Alvarado JA, Weinreb RN, Mitchell MD. Eicosanoid production and glucocorticoid regulatory mechanisms in cultured human trabecular meshwork cells. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:113-38.
4. Shaw BR, Lindsey JD, Weinreb RN. Prostaglandin release in a perfused human anterior segment model. J Glaucoma 1993;2:39-43.
5. Eakins KE. Prostaglandin-like activity in ocular inflammation. Br Med J 1972;3:452-3.
6. Masuda K, Izawa Y, Mishima S. Prostaglandins and glaucomatocyclitic crisis. Jpn J Ophthalmol 1975;19:368-75.
7. Camras CB. Prostaglandins. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis: Mosby-Year Book, 1996:1449-61.
8. Waitzman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. Am J Physiol 1967;212:329-34.
9. Beitch BR, Eakins KE. The effects of prostaglandins on the intraocular pressure of the rabbit. Br J Pharmocol 1969;37:158-67.
10. 1 and aqueous humor dynamics. Invest Ophthalmol 1972;11:1022-7.
11. Starr MS. Further studies on the effect of prostaglandin on intraocular pressure in the rabbit. Exp Eye Res 1971;11:170-7.
12. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 1977;16:1125-34.
13. Bito LZ, Draga A, Blanco DJ, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci 1983;24:312-9.
14. Bito LZ, Camras CB, Gum GG, Resul B. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:349-68.
15. 2α, on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci 1982;22:588-98.
16. Camras CB, Feldman SG, Podos SM, et al. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am J Ophthalmol 1985;100:169-75.
17. Camras CB, Podos SM. The role of endogenous prostaglandins in clinically-used and investigational glaucoma therapy. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:459-75.
18. Gelfand YA, Wolpert M. Effects of topical indomethacin pretreatment on argon laser trabeculoplasty: a randomized, double-masked study on black South Africans. Br J Ophthalmol 1985;69:668-72.
19. Hotchkiss ML, Robin AL, Pollack IP, Quigley HA. Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty. Ophthalmology 1984;91;969-76.
20. 2 and its analogue, BW245C, on intraocular pressure in humans. Graefes Arch Clin Ophthalmol 1991;229:413-41.
21. 2α in the human eye. Graefes Arch Clin Exp Ophthalmol 1985;222:139-41.
22. Stjernschantz J. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. In: Samuelsson B, Ramwell PW, Paoletti R, eds. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. New York: Raven, 1995:63-8.
23. Bito L. Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds. Exp Eye Res 1984;38:181-94.
24. Bito LZ. Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents. In: Drance SM, Neufeld AH, eds. Applied Pharmacology in the Medical Treatment of Glaucoma. Orlando: Grune & Stratton, 1984:477-505.
25. 2α and its isopropylester on normal and glaucomatous human eyes. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:447-58.
26. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991;109: 1564-8.
27. Camras CB, Schumer RA, Marsk A, et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992;110:1733-8.
28. 2α analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76:214-7.
29. Alm A, Villumsen J, Törnquist P, et al. Intraocular pressure reducing effect of PhXA41 in ocular hypertensive patients - a placebo controlled double masked study. Invest Ophthalmol Vis Sci 1992;33(suppl):1247.
30. Alm A, Villumsen J, Törnquist P, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312-6.
31. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs of the Future 1992;17:691.
32. Nagasubramanian S, Seth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993;100: 1305-11.
33. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 1991;35:156-65.
34. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-25.
35. Azuma I. Clinical evaluation of UF-021 ophthalmic solution in glaucoma patients refractory to maximum tolerable therapy. Nippon Ganka Gakkai Zasshi 1993;97:232-8.
36. Fujimori C, Yamabayashi S, Hosoda M, et al. The clinical evaluation of UF-021, a new prostaglandin related compound, in low tension glaucoma patients. Nippon Ganka Gakkai Zasshi 1993;97: 1231-5.
37. Takase M, Murao M, Koyano S, Okita M, Ueno R. Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers. Nippon Ganka Gakkai Zasshi 1992;96:1261-7.
38. 2α derivative, UF-021, and pilocarpine in ocular hypotensive therapy. Nippon Ganka Gakkai Zasshi 1994;98:202-5.
39. Higaki K, Kamata K, Takeuchi M, et al. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative in male white rabbits. Drug Metab Dis 1995;23:35-43.
40. Ando Y, Matsunami C, Yamamoto T, Kitazawa Y. Safety and ocular hypotensive effect of new prostaglandin analogue, S-1033, in normal volunteers. Nippon Ganka Gakkai Zasshi 1994;98: 1109-14.
41. 2α on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci 1984;25:1087-93.
42. 2α on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res 1987;6:1035-44.
43. Kaufman PL. Effects of intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle. Exp Eye Res 1986;43:819-27.
44. 2α-induced ocular hypotension in monkeys. Arch Ophthalmol 1987;105:1112-6.
45. Bill A. Effects of atropine and pilocarpine on aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res 1967;6:120-5.
46. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707-16.
47. 2α-1-isopropylester on uveoscleral outflow. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989:429-36.
48. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402.
49. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
50. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-8.
51. Lütjen-Drecoll E, Kaufman PL. Morphological changes in primate aqueous humor formation and drainage tissues after long-term treatment with antiglaucomatous drugs. J Glaucoma 1993;2:316-28.
52. Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res 1988;47:761-9.
53. Tamm E, Lütjen-Drecoll E, Rohen JW. Age-related changes of the ciliary muscle in comparison with changes induced by treatment with prostaglandin F2 alpha: an ultrastructural study in rhesus and cynomolgus monkeys. Mech Ageing Dev 1990;51:101-20.
54. Svedbergh B, Forsberg I. A morphological study on the effects of chronic administration of latanoprost (LP) on ciliary muscle and trabecular meshwork in monkeys. Invest Ophthalmol Vis Sci 1993; 34(suppl):932.
55. 2α or epinephrine on cynomolgus monkey eyes. III. Histopathology. Invest Ophthalmol Vis Sci 1988;29:1428-36.
56. Mishima HK, Shoge K, Takamatsu M, Kiuchi Y, Tanaka J. Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Am J Ophthalmol 1995;121: 319-21.
57. 2α on calcium efflux. Invest Ophthalmol Vis Sci 1992;33:2679-86.
58. 2α in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1994;35:242-50.
59. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandin increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996;15:869-75.
60. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
61. 2α analogue (PhXA41). Arch Ophthalmol 1993;111:657-61.
62. Watson P, Stjernschantz J, The Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
63. Camras CB. The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
64. Aim A, Stjernschantz J. The Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995;102:1743-52.
65. Camras CB. United States Latanoprost Study Group. Latanoprost treatment for glaucoma: effects of treating for one year and of switching from timolol. Presented at the American Academy Annual Meeting, Chicago, IL, 1996.
66. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103: 1276-82.
67. Sjoquist B, Basu S, Resul B, Stjernschantz J. The pharmacokinetics of latanoprost in the cynomolgus monkey. Invest Ophthalmol Vis Sci 1993;34(suppl):1155.
68. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6.
69. Racz P, Ruzsonyi MR, Nagy ZT, Gagyi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73.
70. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902.
71. Bill A, Walinder PE. The effects of pilocarpine on the dynamics of aqueous humor in a primate. Invest Ophthalmol 1966;5:170-5.
72. Bill A, Phillips CI. Uveoscleral drainage of aqueous humor in human eyes. Exp Eye Res 1971;12:275-81.
73. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-5.
74. 2α analogues on blood-aqueous barrier by measurement of aqueous flare intensity. Invest Ophthalmol Vis Sci 1992;33(suppl):1120.
75. Bito LZ. A physiological approach to glaucoma management: the use of local hormones and the pharmacokinetics of prostaglandin esters. Prog Clin Biol Res 1989;312:329-47.
76. Bito LZ. Glaucoma: a physiologic perspective with Darwinian overtones. J Glaucoma 1992;1:193-205.
77. Becker B. Does hyposecretion of aqueous humor damage the trabecular meshwork? [Editorial]. J Glaucoma 1995;4:303-5.